Compare Citius Pharmaceuticals Inc (CTXR) vs ServiceNow Inc (NOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs ServiceNow Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while ServiceNow Inc trades at $124.7 (market cap $131.86B). The key difference: ServiceNow Inc is far larger — about 6589.7× Citius Pharmaceuticals Inc's market cap, and ServiceNow Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | NOW | |
|---|---|---|
Market Cap | $20.01M | $131.86B |
Sector | Health | Technology |
52-Week High | $1.82 | $192.23 |
52-Week Low | $0.48 | $83.00 |
Enterprise Value | $16.23M | $135.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
ServiceNow (NOW) trades at $127.44, up 2.05% today, with a bullish technical outlook supported by moving averages but overbought RSI signals. Revenue grew to $13.28B in 2025, with a net income margin of 11.34%, though high P/E of 79.71 indicates premium valuation. Recent news highlights AI-driven growth opportunities, including partnerships and conference presentations in June 2026.
The stock offers growth potential from AI adoption and strong cash flows, but faces risks from elevated valuations and competitive pressures. Analyst consensus is strongly bullish with an average price target of $138.26, though investors should monitor earnings consistency and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →
